Newron Pharmaceuticals S.P.A.
Records under this name other than the patents Newron Pharmaceuticals S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 23 patents it holds.
Back to Newron Pharmaceuticals S.P.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,718,815 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders Term ended Term ended Apr 16, 2026 · USPTO record | Term ended | Term ended Apr 16, 2026 | USPTO record |
| US 7,649,005 | Substituted benzylaminoalkylene heterocycles Term ended Term ended Jan 20, 2026 · USPTO record | Term ended | Term ended Jan 20, 2026 | USPTO record |
| US 7,709,523 | Alpha-aminoamide derivatives useful as antimigraine agents Term ended Term ended Oct 14, 2025 · USPTO record | Term ended | Term ended Oct 14, 2025 | USPTO record |
| US 8,445,513 | α-Aminoamide derivatives useful in the treatment of restless legs syndrome Term ended Term ended Sep 29, 2025 · USPTO record | Term ended | Term ended Sep 29, 2025 | USPTO record |
| US 8,697,738 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders Term ended Term ended Apr 19, 2025 · USPTO record | Term ended | Term ended Apr 19, 2025 | USPTO record |
| US 7,265,244 | Cyclopentyl derivatives Term ended Term ended Nov 12, 2024 · USPTO record | Term ended | Term ended Nov 12, 2024 | USPTO record |
| US 8,084,447 | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use Term ended Term ended Sep 25, 2024 · USPTO record | Term ended | Term ended Sep 25, 2024 | USPTO record |
| US 8,901,176 | Methods for treatment of Parkinson's disease Term ended Term ended Apr 8, 2024 · USPTO record | Term ended | Term ended Apr 8, 2024 | USPTO record |
| US 9,492,410 | Methods for treatment of Parkinson's disease Term ended Ended no later than Apr 8, 2024 · USPTO record | Term ended | Ended no later than Apr 8, 2024 | USPTO record |
| US 8,063,039 | 3-aminopyrrolidone derivatives Lapsed on the fee record Ended Nov 22, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 22, 2023 | USPTO record |